PDS Biotechnology (NASDAQ:PDSB) and FibroGen (NASDAQ:FGEN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.
This is a summary of current ratings and price targets for PDS Biotechnology and FibroGen, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares PDS Biotechnology and FibroGen’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
PDS Biotechnology has a beta of 2.26, meaning that its stock price is 126% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500.
Insider and Institutional Ownership
8.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 68.7% of FibroGen shares are owned by institutional investors. 43.9% of PDS Biotechnology shares are owned by insiders. Comparatively, 9.0% of FibroGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares PDS Biotechnology and FibroGen’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|PDS Biotechnology||N/A||N/A||-$40.87 million||($18.00)||-0.15|
|FibroGen||$212.96 million||19.13||-$86.42 million||($1.03)||-45.33|
PDS Biotechnology has higher earnings, but lower revenue than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.
FibroGen beats PDS Biotechnology on 7 of the 13 factors compared between the two stocks.
About PDS Biotechnology
PDS Biotechnology Corporation, a clinical stage immuno-oncology company, develops multifunctional immunotherapeutic products. The company develops products to treat early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its lead product candidate is PDS0101, a monotherapy first line therapy for cervical intraepithelial neoplasia of cancer. In addition, the company develops PDS0102, which is in phase 2 clinical trial for treatment of prostate and breast cancers. Further, its pipeline product portfolio includes PDS0103 for treatment of colorectal, breast, ovarian, and lung cancers; and PDS 0104 for treatment of melanoma. Additionally, the company offers Versamune, a T-cell activating platform developed for immunotherapy approaches, such as checkpoint inhibitors, CAR-T cells and live-vector based vaccines, etc. The company has collaboration agreement with Merck and Co. to combine PDS0101 with Keytruda, a checkpoint inhibitor to treat human papillomavirus positive recurrent or metastatic head and neck cancer. PDS Biotechnology Corporation was incorporated in 2009 and is based in Berkeley Heights, New Jersey.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.